Cargando…

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy

Diabetic retinopathy (DR) is one of the most serious complications of diabetic microangiopathy. DR has an early onset and is not easy to detect. When visual impairment occurs, the optimal period for therapy is often missed. Therefore, the prevention and treatment of DR should start from the early st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sha, Wenjun, Wen, Song, Chen, Lin, Xu, Bilin, Lei, Tao, Zhou, Ligang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676957/ https://www.ncbi.nlm.nih.gov/pubmed/33274239 http://dx.doi.org/10.1155/2020/8867875

Ejemplares similares

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
por: Wołos-Kłosowicz, Katarzyna, et al.
Publicado: (2022)

How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology
por: May, Marcus, et al.
Publicado: (2019)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu, Shuangbo, et al.
Publicado: (2019)

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
por: Pereira, Maria J., et al.
Publicado: (2019)

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
por: Saisho, Yoshifumi
Publicado: (2020)

Direct cardiac effects of SGLT2 inhibitors
por: Chen, Sha, et al.
Publicado: (2022)

The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy
por: Matthews, Jennifer Rose, et al.
Publicado: (2022)

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
por: Li, Na, et al.
Publicado: (2020)

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
por: Androutsakos, Theodoros, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
por: Kowalska, Klaudia, et al.
Publicado: (2022)

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
por: Huang, Keming, et al.
Publicado: (2023)

The Role of SGLT2 Inhibitors in Vascular Aging
por: Liu, Le, et al.
Publicado: (2021)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
por: Gao, Yue-Ming, et al.
Publicado: (2022)

Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
por: Chow, Erica, et al.
Publicado: (2023)

Structural mechanism of SGLT1 inhibitors
por: Niu, Yange, et al.
Publicado: (2022)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
por: Zou, Honghong, et al.
Publicado: (2017)

Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
por: Maki, Toshinobu, et al.
Publicado: (2019)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
por: Theofilis, Panagiotis, et al.
Publicado: (2023)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
por: Podestà, Manuel Alfredo, et al.
Publicado: (2023)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
por: Kawanami, Daiji, et al.
Publicado: (2017)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
por: Evans, Marc, et al.
Publicado: (2019)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
por: Ren, Qian, et al.
Publicado: (2022)

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes
por: Castaneda, Francisco, et al.
Publicado: (2007)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
por: Scisciola, Lucia, et al.
Publicado: (2023)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

A Review on the Relationship between SGLT2 Inhibitors and Cancer
por: Lin, Hao-Wen, et al.
Publicado: (2014)

Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
por: Zou, Honghong, et al.
Publicado: (2018)

Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
por: Sugizaki, Taichi, et al.
Publicado: (2017)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen, Thiquynhnga, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pv4j14ehgdusd7q8m2mc5no734